Description
+ Include: 2 videos + 1 pdf, size: 33.1 GB
+ Target Audience: critical care physican
+ Sample video: contact me for sample video
+ Information:
Following the success of the past 3 editions of the Cardiogenic Shock Workshop, this year’s meeting will take place on Thursday, June 8, ahead of the 3CT Workshop on June 10. The meetings will take place in the Embassy of France in Washington DC.
It will bring together more than 30 high-level experts from North America and Europe and Asia, including representatives from regulatory bodies and government institutions (FDA/EMA/PDMA/NIH) and patients, who will co-author a paper to be published in a high impact factor international journal.
The 3CT Workshop aims to foster an international exchange of ideas where attendees will brainstorm on trial design, conduct, ethics and data interpretation in the critical care area. The sessions will cover domains including drugs, devices, and biomarkers in the field of intensive care.
Following the template of the CVCT workshop, the Critical Care Clinical Trialists (3CT) workshop is a high-level think-tank, with an exceptional expert faculty. It involves a limited number of attendees and includes distinguished intensivists, pulmonologists, cardiologists, emergency physicians, clinical trialists, principal investigators and statisticians from academia, R&D pharma, NIH, EMA and FDA.
I am pleased to announce that for the fourth year running, the proceedings from last year’s Workshop have been accepted for publication in a world leading medical journal.
+ Topics:
*Note: these are continuous video recordings during the conference, they include individual lectures mentioned in the Detail section below
Agenda.pdf
June 8.mp4
June 10.mp4
* Detail:
Friday, June 9, 2023
8:00 AM – 8:30 AM Registration and welcome coffee
8:30 AM – 8:40 AM Welcome introduction by Alexandre Mebazaa (Paris, FRA)
Session 1: Cardiogenic Shock studies: high expectations for 2023
Moderated by Susanna Price (London, GBR) & Benjamin Hibbert (Ottawa, CAN)
8:40 AM – 8:50 AM Trials are important: ECLS shock Holger Thiele (Leipzig, GER)
8:50 AM – 9:00 AM Registries are important David Morrow (Boston, USA)
9:00 AM – 9:10 AM Safety is still a concern Hannah Schaubroeck (Ghent, BEL)
9:10 AM – 9:20 AM Not all Cardiogenic Shock patients are the same Sabri Soussi (Toronto, CAN)
9:20 AM – 9:30 AM DPP3 modulators Karine Bourgeois (4TEEN4, GER)
9:30 AM – 9:35 AM Nurse’s perspective Carolyn Rosner (Falls Church, USA)
9:35 AM – 9:40 AM Patient perspective Rhonda Monroe (Charlotte, USA)
9:40 AM – 10:30 AM Panel discussion with the above as well as FDA, EMA and NIH representatives & more.
10:30 AM – 10:45 AM Coffee break
Session 2: Acute Respiratory Distress Syndrome
Moderated by Diana Stanley (The Lancet Respiratory Medicine Journal, USA) & Gus Matute-Bello (NIH, USA)
10:45 AM – 10:55 AM 2023 Global definition of ARDS Lorraine Ware (Nashville, USA)
10:55 AM – 11:05 AM COVID trials changed study designs: the evidence Samuel Brown (Salt Lake City, USA)
11:05 AM – 11:15 AM Lung Division’s support mechanisms for ARDS trials and research Gus Matute-Bello (NIH, USA)
11:15 AM – 11:25 AM Results of the TESICO trial Christina Barkauskas (Durham, USA)
11:25 AM – 11:35 AM Blue Coral PETAL studies Jack Iwashyna (Baltimore, USA)
11:35 AM – 11:45 AM Precision medicine in the treatment of COVID-19 Bruno François (Limoges, FRA)
11:45 AM – 11:55 AM An Update on PANAMO and EUA for Gohibic (vilobelimab) for the treatment of COVID-19 in hospitalized adults when initiated
within 48 hours of receiving IMV, or ECMO Niels Riedemann (InflaRx, GER)
11:55 AM – 12:00 PM Industry perspective Negin Hajizadeh (Bayer, USA)
12:00 PM – 12:05 PM Patient perspective Eileen Rubin (Chicago, USA)
12:05 PM – 1:00 PM Panel discussion with the above as well as FDA, EMA and NIH representatives & more.
1:00 PM – 2:00 PM Lunch break
Session 3: Worsening Heart Failure
Moderated by Ileana Piña (FDA, USA) & Janine Pöss (Leipzig, GER)
2:00 PM – 2:10 PM Risk Stratification and Safe Early Discharge of Emergency Department Patients with Acute Heart Failure Sean Collins (Nashville, USA)
2:10 PM – 2:20 PM Early initiation of SGLT2 inhibitors to prevent WHF after Hospitalization Zachary Cox (Nashville, USA)
2:20 PM – 2:30 PM How was congestion recorded in recent clinical trials? Megan McLaughlin (San Francisco, USA)
2:30 PM – 2:40 PM Congestion areas primary endpoints Maria Rosa Costanzo (Chicago, USA)
2:40 PM – 2:50 PM Early implementation of GDMT after acute heart failure Alexandre Mebazaa (Paris, FRA)
2:50 PM – 2:55 PM Industry perspective: How to implement guidelines? Hela Ben Hamouda (Medtronic, USA)
2:55 PM – 3:00 PM Industry perspective Harjeet Caberwal (Boehringer Ingleheim, USA)
3:00 PM – 3:05 PM Industry perspective Like Jiang (AstraZeneca, USA)
3:05 PM – 3:10 PM Patient perspective Rhonda Monroe (Charlotte, USA)
3:10 PM – 4:00 PM Panel discussion with the above as well as FDA, EMA and NIH representatives & more.
4:00 PM – 4:30 PM Coffee break
Session 4: Artificial Intelligence: a game changer in critical care
Moderated by Romain Pirracchio (San Francisco, USA) & Michael Harhay (Philadelphia, USA)
4:30 PM – 4:40 PM From AI proof of concept to proof of value: trial design to evaluate AI algorithms Romain Pirracchio (San Francisco, USA)
4:40 PM – 4:50 PM Harnessing Collective Human Intelligence and Imitation Learning to Support Clinical Decisions Gary Weissman (Philadelphia, USA)
4:50 PM – 5:00 PM Risk of algorithmic bias in critical care: how to identify it and mitigate it? Harriette Van Spall (Hamilton, CAN)
5:00 PM – 5:10 PM AI to improve peri-operative therapy Etienne Gayat (Paris, FRA)
5:10 PM – 5:20 PM Home-based diagnosis of heart failure by ultrasound & AI Alexandre Mebazaa (Paris, FRA)
5:20 PM – 5:30 PM Industry perspective Anis Ghorbel (Precisia Care, SUI)
5:30 PM – 6:30 PM Panel discussion with the above as well as FDA, EMA and NIH representatives, scientific journals & more.
6:30 PM Adjourn
6:30 PM – 8:00 PM Dinner in the Embassy of France, Washington D.C.
Saturday, June 10, 2023
8:00 AM – 8:30 AM Welcome coffee
8:30 AM – 8:35 AM Welcome introduction by Alexandre Mebazaa (Paris, FRA)
Session 5: Novelties in Sepsis and Septic Shock:
part A: Preventing organ dysfunction matters
Moderated by Nathan Nielsen (Albuquerque, USA) & Tina Chen (San Francisco, USA)
8:35 AM – 8:45 AM Revival trial: what did we learn? Peter Pickkers (Nijmegen, NED)
8:45 AM – 8.55 AM CAL02 neutralizes toxins Andre Kalil (Omaha, USA)
8:55 AM – 9:05 AM Immunosep: personalized immunotherapy Evangelos Giamarellos-Bourboulis (Athens, GRC)
9:05 AM – 9:45 AM Panel discussion with the above as well as FDA, EMA and NIH representatives & more.
Session 5: Novelties in Sepsis and Septic Shock:
part B: IV therapies are still mandatory
Moderated by Nathan Nielsen (Albuquerque, USA) & Tina Chen (San Francisco, USA)
9:45 AM – 9:55 AM ASTONISH: nangibotide phase IIb final results Bruno François (Limoges, FRA)
9:55 AM – 10:05 AM ACCURATE: phase III design for nangibotide in Septic Shock with a precision medicine approach Mitchell Levy (Providence, USA)
10:05 AM – 10:15 AM Septic shock: BOOST Pierre-François Laterre (Brussels, BEL)
10:15 AM – 10:25 AM Septic shock: i-Micro Matthieu Legrand (San Francisco, USA)
10:25 AM – 11:00 AM Panel discussion with the above as well as FDA, EMA and NIH representatives & more.
11:00 AM – 11:30 AM Coffee break
Session 5: Novelties in Sepsis and Septic Shock:
part C: 2023 primary endpoints in critical care trials:
organ dysfunction, or death or both?
Moderated by Lauren Sorce (Chicago, USA) & Alexandre Mebazaa (Paris, FRA)
11:30 AM – 11:40 AM Improving survival is key Lauren Sorce (Chicago, USA)
11:40 AM – 11:50 AM Industry perspective Margarita Salcedo (Inotrem, FRA)
11:50 AM – 12:00 PM Industry perspective Juliane Bernholz (AM-Pharma, NED)
12:00 PM – 12:10 PM Industry perspective Stefan Witte (Adrenomed, GER)
12:10 PM – 12:20 PM Industry perspective Valentin Curt (Eagle Pharmaceuticals, USA)
12:20 PM – 1:00 PM Panel discussion with the above as well as FDA, EMA and NIH representatives & more.
1:00 PM Adjourn
Reviews
There are no reviews yet.